SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: donald barton who wrote (429)8/17/1997 12:55:00 PM
From: John Zwiener   of 1115
 
HI Don.
As CEO Katz says, we have steadfastly refrained from releasing the structure of our licensing agreements, and continue to do so. They have been a stone wall on this subject. (I don't know if it's an unusally good agreement or bad or average).I guessed the royalty rate low-average or 6%. The contract manufacturer hired by Lidak to make the drug in Lidak's name will produce lidakol whick Lidak will then sell to BMS, Yamanuchi, CTIS, etc. Half of the revenue could come from this area. Maybe more. Depends on BMS royalty.

Maybe lidak won't release the royalty numbers because the licensees don't want others to know what they have been willing to pay in the past.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News